1 H NMR (400 MHz, D 2 O) 7.78 (s, 2H), 7.01 (s, 2H), 4.71 4.60 (m, 2H), 4.44 4.03 (m, 3H), 3.80 3.74 (m, 4H), 3.32 2.88 (m, 10H), 1.85 1.11 (m, 18H) 13 .C NMR (151 MHz, D 2 O) 178.88, 172.79, 172.16, 172.10, 167.38, 167.21, 134.76, 134.56, 129.96, 129.66, 117.45, 54.20, 54.17, 53.68, 53.46, 53.08, 40.64, 40.59, 39.33, 39.28, 37.38, 30.79, 30.39, 30.37, 28.05, 27.65, 27.48, 27.40, 22.63, 22.18, 22.04
(October 2021)
If you'd like to learn more about the details, check the uLipSync repository
The GI side effect rates are roughly comparable at effective doses
As an investigational compound, it has not yet received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA), and its use remains confined to clinical research settings